Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 3
1990 6
1991 1
1992 4
1993 1
1994 1
1995 2
1996 2
1997 3
1998 2
1999 2
2000 5
2001 2
2002 2
2003 1
2004 3
2005 3
2006 3
2007 3
2008 1
2009 1
2010 5
2011 8
2012 6
2013 6
2014 15
2015 17
2016 18
2017 13
2018 18
2019 25
2020 22
2021 32
2022 28
2023 18
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

245 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %, %, %
The following terms were not found in PubMed: 20Rodr, ADguez-Di, A9guez
Page 1
Transcranial magnetic stimulation of the brain: What is stimulated? - A consensus and critical position paper.
Siebner HR, Funke K, Aberra AS, Antal A, Bestmann S, Chen R, Classen J, Davare M, Di Lazzaro V, Fox PT, Hallett M, Karabanov AN, Kesselheim J, Beck MM, Koch G, Liebetanz D, Meunier S, Miniussi C, Paulus W, Peterchev AV, Popa T, Ridding MC, Thielscher A, Ziemann U, Rothwell JC, Ugawa Y. Siebner HR, et al. Clin Neurophysiol. 2022 Aug;140:59-97. doi: 10.1016/j.clinph.2022.04.022. Epub 2022 May 18. Clin Neurophysiol. 2022. PMID: 35738037 Free PMC article. Review.
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.
Harrison SA, Ruane PJ, Freilich B, Neff G, Patil R, Behling C, Hu C, Shringarpure R, de Temple B, Fong E, Tillman EJ, Rolph T, Cheng A, Yale K. Harrison SA, et al. JHEP Rep. 2022 Aug 23;5(1):100563. doi: 10.1016/j.jhepr.2022.100563. eCollection 2023 Jan. JHEP Rep. 2022. PMID: 36644237 Free PMC article.
Sixteen-week treatment with efruxifermin was associated with significant reductions in non-invasive markers of fibrosis including Pro-C3 (least squares mean change from baseline [LSMCFB] -9 mug/L efruxifermin vs. -3.4 mug/L placebo; p = 0.0130) and ELF score (-0.4 efruxife …
Sixteen-week treatment with efruxifermin was associated with significant reductions in non-invasive markers of fibrosis including Pro-C3 …
Pemphigoid Gestationis.
Agostinis P, Antonello RM. Agostinis P, et al. N Engl J Med. 2020 Aug 27;383(9):e61. doi: 10.1056/NEJMicm2000922. N Engl J Med. 2020. PMID: 32846065 No abstract available.
Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial.
Mozaffarian D, Maki KC, Bays HE, Aguilera F, Gould G, Hegele RA, Moriarty PM, Robinson JG, Shi P, Tur JF, Lapointe JF, Aziz S, Lemieux P; TRILOGY (Study of CaPre in Lowering Very High Triglycerides) investigators. Mozaffarian D, et al. JAMA Netw Open. 2022 Jan 4;5(1):e2141898. doi: 10.1001/jamanetworkopen.2021.41898. JAMA Netw Open. 2022. PMID: 34989797 Free PMC article. Clinical Trial.
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1.
Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, Abeliovich H, Abildgaard MH, Abudu YP, Acevedo-Arozena A, Adamopoulos IE, Adeli K, Adolph TE, Adornetto A, Aflaki E, Agam G, Agarwal A, Aggarwal BB, Agnello M, Agostinis P, Agrewala JN, Agrotis A, Aguilar PV, Ahmad ST, Ahmed ZM, Ahumada-Castro U, Aits S, Aizawa S, Akkoc Y, Akoumianaki T, Akpinar HA, Al-Abd AM, Al-Akra L, Al-Gharaibeh A, Alaoui-Jamali MA, Alberti S, Alcocer-Gómez E, Alessandri C, Ali M, Alim Al-Bari MA, Aliwaini S, Alizadeh J, Almacellas E, Almasan A, Alonso A, Alonso GD, Altan-Bonnet N, Altieri DC, Álvarez ÉMC, Alves S, Alves da Costa C, Alzaharna MM, Amadio M, Amantini C, Amaral C, Ambrosio S, Amer AO, Ammanathan V, An Z, Andersen SU, Andrabi SA, Andrade-Silva M, Andres AM, Angelini S, Ann D, Anozie UC, Ansari MY, Antas P, Antebi A, Antón Z, Anwar T, Apetoh L, Apostolova N, Araki T, Araki Y, Arasaki K, Araújo WL, Araya J, Arden C, Arévalo MA, Arguelles S, Arias E, Arikkath J, Arimoto H, Ariosa AR, Armstrong-James D, Arnauné-Pelloquin L, Aroca A, Arroyo DS, Arsov I, Artero R, Asaro DML, Aschner M, Ashrafizadeh M, Ashur-Fabian O, Atanasov AG, Au AK, Auberger P, Auner HW, Aurelian L, Autelli R… See abstract for full author list ➔ Klionsky DJ, et al. Autophagy. 2021 Jan;17(1):1-382. doi: 10.1080/15548627.2020.1797280. Epub 2021 Feb 8. Autophagy. 2021. PMID: 33634751 Free PMC article.
Fluorinated metal-organic frameworks for gas separation.
Ebadi Amooghin A, Sanaeepur H, Luque R, Garcia H, Chen B. Ebadi Amooghin A, et al. Chem Soc Rev. 2022 Aug 30;51(17):7427-7508. doi: 10.1039/d2cs00442a. Chem Soc Rev. 2022. PMID: 35920324 Review.
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study.
Loomba R, Lawitz EJ, Frias JP, Ortiz-Lasanta G, Johansson L, Franey BB, Morrow L, Rosenstock M, Hartsfield CL, Chen CY, Tseng L, Charlton RW, Mansbach H, Margalit M. Loomba R, et al. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):120-132. doi: 10.1016/S2468-1253(22)00347-8. Epub 2022 Dec 12. Lancet Gastroenterol Hepatol. 2023. PMID: 36521501 Clinical Trial.
Significant improvements were also observed with pegozafermin treatment for triglycerides (9 mg once weekly, 27 mg once weekly, and 18 mg once every 2 weeks), LDL-C (9 mg once weekly and 27 mg once weekly), HDL-C (3 mg once weekly and 18 mg once every 2 weeks), non-HDL-C (9 mg on …
Significant improvements were also observed with pegozafermin treatment for triglycerides (9 mg once weekly, 27 mg once weekly, and 18 mg on …
Complement levels during the first trimester predict disease flare and adverse pregnancy outcomes in systemic lupus erythematosus: A network meta-analysis on 532 pregnancies.
Radin M, Cecchi I, Crisafulli F, Klumb EM, de Jesús GR, Lacerda MI, Saavedra MÁ, Reyes-Navarro GV, Iaccarino L, Larosa M, Moroni G, Tamborini F, Roccatello D, Andreoli L, Sciascia S, Chighizola CB. Radin M, et al. Autoimmun Rev. 2023 Dec;22(12):103467. doi: 10.1016/j.autrev.2023.103467. Epub 2023 Oct 17. Autoimmun Rev. 2023. PMID: 37852515 Free article. Review.
RESULTS: A total of 532 lupus women from four studies were included in the analysis. In SLE women, C3 and C4 increased progressively during gestation: levels remained stable during T1 and peaked in T2 to decrease in T3. ...Both reduction and the lack of increase of C3 …
RESULTS: A total of 532 lupus women from four studies were included in the analysis. In SLE women, C3 and C4 increased progressively …
C3-targeted host-modulation approaches to oral inflammatory conditions.
Kajikawa T, Mastellos DC, Hasturk H, Kotsakis GA, Yancopoulou D, Lambris JD, Hajishengallis G. Kajikawa T, et al. Semin Immunol. 2022 Jan;59:101608. doi: 10.1016/j.smim.2022.101608. Epub 2022 Jun 9. Semin Immunol. 2022. PMID: 35691883 Review.
This review places emphasis on a promising periodontal host-modulation therapy targeting the complement system, namely the complement C3-targeting drug, AMY-101. AMY-101 has shown safety and efficacy in reducing gingival inflammation in a recent Phase 2a clinical study. .. …
This review places emphasis on a promising periodontal host-modulation therapy targeting the complement system, namely the complement C3 …
Non-invasive testing and risk-stratification in patients with MASLD.
Zoncapè M, Liguori A, Tsochatzis EA. Zoncapè M, et al. Eur J Intern Med. 2024 Apr;122:11-19. doi: 10.1016/j.ejim.2024.01.013. Epub 2024 Jan 20. Eur J Intern Med. 2024. PMID: 38246813 Review.
These NITs include a variety of approaches, such as serum markers like FIB-4, pro-C3 and ELF, imaging techniques like Fibroscan and MRE, and combined scores like Agile 3+ and Agile 4, offering a range of options for healthcare providers. ...
These NITs include a variety of approaches, such as serum markers like FIB-4, pro-C3 and ELF, imaging techniques like Fibroscan and M …
245 results